Conolidine’s analgesic effects stem from its conversation with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors while in the central nervous program, conolidine modulates alternate molecular targets. A Science Improvements study identified that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://tonyx197qst6.blogdal.com/profile